Reuters logo
3 years ago
BRIEF-Galapagos says favorable data for phase 1 inflammatory bowel disease drug
October 20, 2014 / 5:46 AM / 3 years ago

BRIEF-Galapagos says favorable data for phase 1 inflammatory bowel disease drug

Oct 20 (Reuters) - Galapagos NV

* Galapagos NV : Galapagos discloses novel target and presents favorable phase 1 data for GLPG1205 at UEG week

* Discloses GPR84 as a promising novel target for treating inflammatory bowel disease

* GLPG1205 shows strong efficacy in relevant pre-clinical models for IBD Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below